Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

ICORG has its 4th New England Journal of Medicine Publication

ICORG’s 4th NEJM Publication is now available and it’s exciting news for some Lung Cancer patients.

The study [ICORG 10-18] investigated Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. It concluded that Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non–small-cell lung cancer with ALK rearrangement.

The ICORG Principal Investigator was Prof. Ken O’Byrne. Click here to view the abstract 

Leave a Reply

Your email address will not be published.